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Background: Neurosurgical site infections result in prolonged hospitalisation and increased treatment costs. Cost of 
illness studies are important in computing the total costs of treatment of disease, as they quantify the burden of 
disease in terms of direct costs, productivity losses and intangible costs. Neurosurgical site infections do not occur at a 
high rate in most clinical settings. Their economic impact has been assumed to be minimal, and most studies have not 
exclusively studied their economic impact.  
Objective: To assess the economic burden of treatment of surgical site infections among trauma patients admitted at 
the neurosurgical ward of Kenyatta National Hospital.  
Methods: A prospective cost of illness study was conducted between April 2015 and June 2015 as part of a larger 
prospective cohort study. The patient perspective was adopted. The time horizon was the hospitalization period of the 
patients, which was a median of ten days. No discounting was done because the study was done within a year. A micro 
costing approach was used to compute direct costs on medication, laboratory and radiologic tests, cost of surgical 
procedures and nursing care, and direct non-medical costs incurred by patients for the average 10 day hospitalisation 
period. Productivity losses were also computed.  
Results: The total median cost of treating patients with neurosurgical site infections was higher, at USD 203.95 than 
that of patients without infection at USD 141.20. The median cost on antibiotics was USD 18.70 while that of non- 
antibiotic drugs was USD 33.03. The total median cost on laboratory and radiologic tests was USD 20 and USD 55 
respectively. The key cost drivers were expenditures on meropenem, phenytoin, urea, electrolyte and creatinine tests 
and CT scans. With regards to costs of services, care-giver costs accounted for the highest median expenditure, 
followed by costs of surgery and nursing care. 
Conclusion: Neurosurgical site infections increase hospitalisation duration and costs. Prevention of these will reduce 
patient expenditure.  
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1. Introduction 
Surgical site infections occur at and beyond the site of 
surgical incision after surgery. Neurosurgical site 
infections generally have a low incidence, but when 
they occur, they are associated with high morbidity and 
mortality rates, prolonged hospital stay and increased 
costs (Chiang et al, 2014). The cost of surgical site 
infections per year has been estimated to range from 1 
to 10 billion US dollars and its monetary equivalents in 
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direct costs and productivity losses (Perencevich et al, 
2003; Shepard et al, 2013). The average cost of 
treatment of a single surgical site infection in America 
has been estimated to be 2,734 US dollars (Shepard et 
al, 2013).  
The cost of treatment of surgical site infection depends 
on the site of the infection. The estimated cost of 
treating a superficial SSI is 400 US dollars per case, 
while that of treating an organ/space infection has been 
estimated to be 30,000 US dollars per case (Urban, 
2006). There is paucity of data on the cost of treatment 
of neurosurgical site infections in both high and low 
income countries. Costs of illness studies are important 
as they quantify the direct costs and productivity losses 
incurred with specific diseases and provide data for 
planning and resource allocation to governments and 
health institutions. Generally, since neurosurgical site 
infections are of low incidence, their economic impact 
has not been studied. This study will provide data that 
will aid hospitals in developing countries in allocating 
resources that would be used in treatment and 
prevention of neurosurgical site infections.  
This study sought to compute the expenditure on 
antibiotics and other medications, diagnostic tests and 
productivity losses incurred due to hospitalization; 
compare the expenditure in patients with surgical site 
infections and those without and identify the key cost 
drivers. 
2. Methods 
2.1 Study Design and Population 
A prospective cost of illness cohort study of adult 
trauma patients admitted at the neurosurgical unit 
between April and June 2015 was conducted.   
2.2 Eligibility criteria 
Patients who met the following criteria were included in 
the study: adult patients over 18 years old, those who 
sustained traumatic injury through road traffic 
accidents, assault, falls or any other cause,  those who 
had contaminated to dirty wounds and were admitted 
at the KNH neuro-intensive care unit and ward 4C for 
elective and emergency neurosurgery in the study 
period. Paediatric patients, those with clean wounds 
and those who underwent neurosurgery for reasons 
other than trauma were excluded. 
2.3 Sampling Strategies and Sample Size 
The investigator perused through patient files in the 
neurosurgical ward to identify patients who had been 
admitted due to trauma. Universal sampling was used 
such that all patients who met the inclusion criteria 
were included in the study. Consent was sought from 
patients and/or caregivers before recruitment into the 
study. A sample size of 100 patients was estimated 
using the formula for incidence (Daniel, 2010). 
2.4 Data Collection 
The investigator perused through patient files and 
documented the types of drugs prescribed to the 
patients and the laboratory and radiological tests they 
had undergone. The costs of each item were obtained 
from the Kenyatta National patient charge sheets for the 
surgical division and the acquisition lists for drugs. 
Where the patients underwent tests or obtained drugs 
outside the hospital, the information was obtained by 
history taking from the patients and/or caregivers.  
2.5 Data Analysis 
The patient perspective was adopted and this included 
all costs incurred by the patients during treatment.  The 
time horizon was defined as the time between 
admission and discharge. No discounting of costs was 
done because the study was done in less than one year.  
A micro costing approach was used to compute direct 
costs. Most of the quantities and prices of resources 
consumed were obtained from the participant files. We 
computed the direct costs which included the following 
categories of expenditure: surgery, bed occupancy, 
nursing care, medicines, laboratory and diagnostic tests.  
For the direct non-medical costs, we computed costs 
incurred on food and transport for patients and their 
caregivers during the hospitalization period.  
To compute the expenditure on medicines, the 2014 
acquisition price lists of Kenyatta National Hospital 
were used to obtain unit prices of the medicines. The 
final price was computed as a product of the price of 
unit dose, number of unit doses, frequency of 
administration and duration of administration. Where 
there was missing data on the dose, duration, frequency 
and route of administration, imputation was done by 
replacing the missing data with the median dose, 
frequency, route and duration of use. To calculate the 
costs incurred by the patients, we used a mark -up of 
30%.  
To obtain prices of laboratory and radiological tests, 
expenditure on transport and food, we inquired from 
patients as these were not recorded in their files.  
Productivity losses were calculated using the human 
capital approach, as a product of daily income and the 
hospitalization days, with 30 days allowed for 
recuperation. The estimated daily income was obtained 
by participant interview.  Overhead costs such as 
administrative charges, utilities such as water and 
electricity were ignored. 
2.6 Ethical Considerations 
Approval to carry out this study was sought from the 
Kenyatta National Hospital/ University of Nairobi Ethics 
Review Committee, no P76/02/2014.  
3. Results  
Care-giver costs accounted for the highest median 
expenditure, followed by costs of surgery and nursing 
care. Expenditure on non-antibiotic drugs like anti-
seizure drugs, drugs for raised intracranial pressure, 
haematinics and vitamin supplements accounted for the 
least expenditure, as presented in Table 1. One US 
dollar is equivalent to KES 100. 
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    Table 1: Summary of all costs incurred  
Type of costs Median costs [IQ], KES. Median costs, US Dollars (USD) 
Antibiotics 
Non  antibiotics 





3303.09 [ 1177.98, 8956.39] 
1870.05 [1539.41, 4805.11] 
42,200 
2000 [1700, 5700] 
5500 [5500, 13000] 
81,900 
12,250 [0, 70,000] 
33.03 [11.78, 89.56] 
18.70 [15.39, 48.05] 
422.00 
20.00 [17.00, 57.00] 
55.00 [55.00, 130.00] 
819.00 
12.25 [0, 700.00] 
 
Comparison of expenditure in patients with and 
without surgical site infection  
A comparison was made between the total costs of all 
the procedures for patients who developed surgical site 
infections and those who did not. Of note, the median 
total costs, for each type, were higher in the group 
which developed infection, as shown in Table 2. As 
expected, there was a statistically significant association 
between the total expenditure (p=0.028), total direct 
medical cost (p= 0.004), the total cost of medicine 
(p=0.026) and surgical site infection.  
There was no statistically significant difference between 
the total costs of radiological tests, laboratory tests non-
medical costs, and presence of surgical site infections. 
This is expected because radiologic and laboratory tests 
can be ordered for any other reason apart from 
diagnosis of infection. However, when individual 
laboratory tests were considered, there was a 
statistically significant difference between the 
expenditure on full blood count and surgical site 
infection (p=0.010). There was no association between 
direct medical costs and surgical site infection as 
presented in Table 2. 
 
Table 2: Comparison of the total costs between those who developed surgical site infection and those who did not 
Type of  total cost 
Median [IQR] Expenditure , No 
infection (KES) 
Median [IQR] Expenditure, Infection 
(KES.) 
P value 
Total cost 14119.84 [11495.46,21280.0], n=49 
USD 141.19[114.95, 212.80] 
20394.61[14022.42, 28500, n=24 
USD 203.94[140.22, 285.00] 
0.028 
Total direct medical 
cost 
9800 [ 8166.9, 13362.6], n=51 
USD 98.00[81.67, 133.62] 
12483.52[9333.64,  26127.67], n=27 
USD 124.83 [93.33, 261.27] 
0.004 
Total medicines cost 906.14 [0, 3150.76], n=53 
USD 90.61[0, 31.50] 
2483.185[502.58, 8616.65], n=28 
USD 24.83[50.26, 86.17] 
0.026 
Total radiologic tests 5500[5500,7000], n=53 
USD 55.00[55.00, 70.00] 
5500[5500,8000], n=27 
USD 55.00[55.00, 80.00] 
0.574 
Total lab tests 1800[1600, 2800], n=53 
USD 18.00[16.00, 28.00] 
2250 [1650, 2850], n=28 
USD 22.50 [16.50, 28.50] 
0.683 
Total non- medical 
costs 
2400[0,7600], n=51 
USD 24.00[0. 76.00] 
4200 [1750, 5940], n=25 
USD 42.00[17.50, 59.40] 
0.158 
 
Key Cost Drivers for Medicines and Laboratory tests 
We identified the key cost drivers among antibiotics, 
non-antibiotics, laboratory and radiologic tests. For 
antibiotics, meropenem was the key cost driver, 
accounting for 92.5 % of the total cost of antibiotics. 
Similarly, phenytoin accounted for 15% of the 
expenditure on non-antibiotics as the key cost driver. 
Urea, electrolyte and creatinine (UECs) tests accounted 
for a large proportion of expenditure on laboratory 
tests, because about 36.8% of all the patients 
underwent this test, with a maximum of about 41.1% 
(median 36.8%, IQ 25.0% to 41.1%). This was followed 
by liver function tests (median 25.9%, IQ 14.6% to 
41.2%) and full blood count (median 12.0%, IQ 7.7% to 
16.7%). All patients (100.0%) underwent at least one 
CT scan, making it a key cost driver for radiologic tests. 
4.0 Discussion 
Our study computed the costs of treatment of 
neurosurgical patients only. This is unlike other studies 
which computed the costs of treatment of patients 
undergoing different types of surgeries (Ulu- Kilic et al, 
2015; Wang et al, 2015; Borzkut et al, 2013; Collins, 
2013; Shepard et al, 2013, Sharma et al, 2012; Hanstein 
et al, 2011). There were no studies that computed the 
costs of treatment of neurosurgical patients alone. Most 
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of these studies also computed costs across different 
hospitals, unlike our study which was a single centre 
study (Shepard et al, 2013, Wang et al, 2015; Ulu- Kilic 
et al, 2015; Collins, 2013; Sharma et al, 2012; Hanstein 
et al, 2011).  
The costs in our study appear much lower than the 
expenditure quoted in similar studies, most of which 
have quoted prices amounting to thousands of US 
dollars (Ulu- Kilic et al, 2015; Collins, 2013; Sharma et 
al, 2012; Borzkut et al, 2013). This can be attributed to 
the short duration of hospital stay for our patients, 
which we used to calculate the costs, compared to other 
studies which computed costs of hospitalisation for 
months or years. The subsidised cost of antibiotics 
could also explain the relatively low costs of treatment. 
Kenyatta National Hospital mainly procures generic 
antibiotics for the patients in the general wards, which 
are much cheaper than their original versions. Our 
study also had a small sample size and estimated the 
costs in a small unit of a major hospital, compared to the 
other studies which estimated either costs of large 
populations of surgical patients in multiple hospitals 
(Wang et al, 2015; Borzkurt et al, 2013; Shepard et al, 
2013; Sharma et al, 2012; Hanstein et al, 2011).  
A very old study reported that in the recent years, the 
cost of radiologic tests has risen and forms a huge part 
of patient health expenditure. This is particularly so, 
considering the routine use of more sophisticated tests 
such as CT scans and MRI scans (Hofman et al, 2000). 
This can be mirrored in our study in which CT scans 
were mostly used for diagnosis. Radiologic tests were 
the fourth most costly intervention after surgical and 
nursing procedures and bed occupancy.  
Another old study computed the costs of several 
radiologic examinations (Saini et al, 2000). The costs 
were a computation of labour and non-labour costs. The 
average cost radiography, CT scan and MRI was USD 41, 
112 and 267 respectively. These charges are much 
higher than the costs of these tests in our study. This 
can be explained by the fact that after introduction of 
these tests, the costs have significantly gone down over 
the years. A newer study has advocated for the 
reduction in the number of radiological examinations 
done as they increase health care costs and expose 
patients to unnecessary radiation (Kendall and Quill, 
2014). This however should not overlook the 
importance of radiological tests in informing diagnosis 
and guiding treatment (Hofman et al, 2000). Variations 
in the cost of radiologic and laboratory examinations 
were seen in our study, depending on the site where the 
patients underwent the test. This is also seen in studies 
which showed such variations (Spence et al, 2014; 
Chatterjee et al, 2013).   
The median cost of antibiotics was KES. 1,870.05 (18.70 
US dollars). In the study period, 50 patients were on 
antibiotics, and 22 of them developed infection. The 
total median cost therefore, of treating all the infected 
patients with antibiotics (n=22) was KES 41,141.10, as 
opposed to KES. 52,361.40 for those who did not 
develop infections (n=28). These findings are contrary 
to several studies which show that the cost of 
antibiotics increases with those who have developed 
infection (Bozkurt et al, 2013; Sharma et al, 2012; Ulu- 
Kilic et al, 2015). Looking at our antibiotic consumption 
data, it is clear that antibiotics were given equally to 
patients, regardless of whether they developed infection 
or not, suggesting indiscriminate antibiotic use or an 
increase in use of antibiotics for prophylaxis rather than 
for treatment. More patients without infections received 
multiple antibiotics, compared to those who developed 
infections, because those who developed infections 
were fewer than those who did not.  
Although the cost on antibiotics was higher in the 
patients who did not develop infections, the overall cost 
of treating infected patients was higher than that of 
treating uninfected patients. This included the direct 
medical costs, productivity losses and direct non-
medical costs. These findings agree with other studies 
(Shepard et al, 2013; Sharma et al, 2012).  
Apart from direct medical costs, patients spent a 
median of KES. 100 and KES 200 on food and transport 
respectively, for the relatives who visited them in 
hospital. This is against a median daily income of KES. 
300. This shows that these costs literally took up all the 
income for the day. Even though Kenyatta National 
hospital provides meals for all its patients, the relatives 
opted to supplement that with food bought from 
outside the hospital. This increased the household 
income spent on taking care of the ill.  
The patients were employed in low paying jobs, with a 
median average daily income of KES 300. The 
productivity costs were very high, almost a third of the 
direct medical costs. This finding is contrary to that in 
other studies that have stated that productivity losses 
can be higher than direct medical costs (Changik, 2014). 
This is because such studies have been carried out in 
high income areas where patients are on high salaries 
and the cost of replacing them during the illness and 
recuperation period is high. Our patients worked menial 
jobs with no fixed salaries, so they could easily be 
replaced by other casual labourers at the time of illness.  
In this study, the costs of medicines, diagnostic tests, 
surgery and nursing care, direct non-medical costs and 
productivity losses were computed. Care giver costs 
were the highest, followed by costs of surgical and 
nursing procedures and productivity losses. The cost on 
medicines was the lowest. They key cost drivers for 
laboratory, radiologic procedures and medicines were 
CT scans, UECs and meropenem respectively. The total 
expenditures were higher in patients who developed 
infection than patients who did not. Patients who 
underwent full blood count tests were likely to be 
infected. Productivity losses and cost of hiring 
caregivers was higher than the patients’ income. 
From our study, it is evident that the costs of treating a 
neurosurgical trauma patient were much higher than 
the patients’ household incomes, assuming that the 
daily income is a reflection of household income. This is 
against the fact that the Kenyan healthcare system 
heavily relies on out of pocket payments for healthcare 
(Chuma and Okungu, 2011). The Ministry of health is 
underfunded and cannot take care of the costs of all 
patients. The National Health Insurance Fund (NHIF) 
pays for some inpatient costs of patients, but only caters 
for inpatient hospital stay. Some hospitals, Kenyatta 
National Hospital included, have adopted a waiver 
system to take care of the costs of extremely poor 
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patients, but this still has challenges as they are not able 
to cover the costs of all patients (Kamanda et al, 2015). 
This calls for a revision in healthcare financing policies 
in Kenya, to meet the WHO standards for equity in 
healthcare (Chuma and Okungu, 2011).  
The limitation for this study was that intangible costs 
were not computed. This is because we were unable to 
interview some of the patients with head trauma 
because of low Glasgow coma scores, confusional states 
and general disorientation which was associated with 
head injury. 
5.0 Conclusion  
Neurotrauma and associated surgical site infections 
affect the youth of productive age in developing 
countries. The direct costs of treatment, and household 
expenses incurred are a heavy burden to the patients 
and their families, most of whom cannot afford the out 
of pocket expenses. The productivity losses are also 
high, although the patients in this cohort were not 
employed in jobs with a steady income. Costs due to 
antibiotic use are higher in the patients who do not 
develop infections than those who develop infections. 
This points to irrational antibiotic use or increased use 
of antibiotics for prophylaxis, which is associated with 
unnecessary costs. The costs of diagnostic tests do not 
vary with infection rates, but vary with the site at which 
the tests are done. The acquisition costs of some 
medicines varied with the year. 
Hospitals carrying out neurosurgical procedures and 
governments in developing countries at large should 
come up with comprehensive insurance schemes to 
cater for the healthcare costs of this group of patients. 
As discussed earlier, irrational antibiotic use 
contributed to an increase in medication costs. The 
neurosurgical units should develop antibiotic use 
guidelines for their patients to ensure rational and 
economic use of medicines. The hospital tender 
committees should evaluate yearly acquisition prices of 
all the medication to prevent the wide variations in 
prices seen in some medications. Finally, a study should 
be carried out to compute the intangible costs incurred 
by neurosurgical trauma patients in developing 
countries. 
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